LLY

775.79

-0.45%↓

JNJ

155.7

+2.05%↑

NVO

69.84

+1.19%↑

ABBV

189.81

+2.22%↑

UNH

325.71

+4.47%↑

LLY

775.79

-0.45%↓

JNJ

155.7

+2.05%↑

NVO

69.84

+1.19%↑

ABBV

189.81

+2.22%↑

UNH

325.71

+4.47%↑

LLY

775.79

-0.45%↓

JNJ

155.7

+2.05%↑

NVO

69.84

+1.19%↑

ABBV

189.81

+2.22%↑

UNH

325.71

+4.47%↑

LLY

775.79

-0.45%↓

JNJ

155.7

+2.05%↑

NVO

69.84

+1.19%↑

ABBV

189.81

+2.22%↑

UNH

325.71

+4.47%↑

LLY

775.79

-0.45%↓

JNJ

155.7

+2.05%↑

NVO

69.84

+1.19%↑

ABBV

189.81

+2.22%↑

UNH

325.71

+4.47%↑

Search

GlycoMimetics Inc

Fermé

SecteurSoins de santé

0.15

Résumé

Variation du prix de l'action

24h

Actuel

Min

0.13

Max

0.15

Chiffres clés

By Trading Economics

Revenu

-2.3B

-2.3B

BPA

-0.04

Marge bénéficiaire

-13,354.199

Employés

4

EBITDA

2.9M

-2.4M

Recommandations

By TipRanks

Recommandations

Achat

Prévisions sur 12 Mois

+43.79% upside

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

10M

Ouverture précédente

0.15

Clôture précédente

0.15

Score Technique

By Trading Central

Confiance

Bearish Evidence

GlycoMimetics Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

26 juin 2025, 23:49 UTC

Résultats

Nike Sees Sales Decline Decelerating in 1Q as Turnaround Strategy Plays Out -- 2nd Update

26 juin 2025, 22:19 UTC

Acquisitions, Fusions, Rachats

FTC Clears Alimentation Couche-Tard's $1.57 Billion GetGo Acquisition

26 juin 2025, 21:30 UTC

Résultats

Nike 4Q Profit, Revenue Slides as Turnaround Strategy Plays Out -- Update

26 juin 2025, 21:07 UTC

Résultats

Nike 4Q Profit, Revenue Slide as Turnaround Strategy Plays Out

26 juin 2025, 23:49 UTC

Market Talk

Nikkei May Rise as Fears About Middle East Conflict Ebb -- Market Talk

26 juin 2025, 23:39 UTC

Market Talk

Gold Edges Lower, Weighed by Stronger-Than-Expected U.S. Data -- Market Talk

26 juin 2025, 23:34 UTC

Acquisitions, Fusions, Rachats

Wesfarmers: Lease Reset Provides Opportunity for Upgrades, Extensions

26 juin 2025, 23:33 UTC

Acquisitions, Fusions, Rachats

Wesfarmers: 62 BWP-Owned Bunnings Sites Get Significantly Longer Leases

26 juin 2025, 23:32 UTC

Acquisitions, Fusions, Rachats

Wesfarmers Will No Longer Receive Earnings From BWP Management

26 juin 2025, 23:32 UTC

Acquisitions, Fusions, Rachats

Wesfarmers to Increase BWP Holding to 23.5% From 22.3%

26 juin 2025, 23:31 UTC

Acquisitions, Fusions, Rachats

Wesfarmers: New BWP Units Priced at 9.2% Premium to Last Close

26 juin 2025, 23:31 UTC

Acquisitions, Fusions, Rachats

BWP to Pay A$100 Mln Cash, A$42.6 Mln in New Units

26 juin 2025, 23:30 UTC

Acquisitions, Fusions, Rachats

Wesfarmers' Bunnings, BWP Trust to Extend and Vary Leases

26 juin 2025, 23:29 UTC

Acquisitions, Fusions, Rachats

Wesfarmers to Sell BWP Management to BWP Trust for A$142.6M

26 juin 2025, 23:19 UTC

Acquisitions, Fusions, Rachats

Andlauer Healthcare Group: Ontario Superior Court of Justice Issues Final Order Approving Sale to UPS

26 juin 2025, 22:06 UTC

Résultats

Nike's Earnings Were Ugly. But They're Better Than Feared. -- Barrons.com

26 juin 2025, 21:15 UTC

Résultats

Nike 4Q Profit, Rev Slides as Turnaround Strategy Plays Out -- Update

26 juin 2025, 21:07 UTC

Acquisitions, Fusions, Rachats

Couche-Tard: 35 Stores to Be Divested in Accordance With Regulatory Requirements >ATD.T

26 juin 2025, 21:07 UTC

Acquisitions, Fusions, Rachats

Couche-Tard: GetGo Will Operate as Separate, Stand-Alone Business Unit, Maintain myPerks Loyalty Program >ATD.T

26 juin 2025, 21:07 UTC

Acquisitions, Fusions, Rachats

Couche-Tard: Buyer Will be Approved by the FTC >ATD.T

26 juin 2025, 21:07 UTC

Résultats

Nike's Earnings Were Ugly. But They're Better Than Feared. -- Barrons.com

26 juin 2025, 21:06 UTC

Acquisitions, Fusions, Rachats

Couche-Tard Agreed to Sell 35 Sites, Including 34 Circle K Locations and One GetGo Property >ATD.T

26 juin 2025, 21:06 UTC

Acquisitions, Fusions, Rachats

Couche-Tard: Transaction Is Expected to Close in the Coming Days >ATD.T

26 juin 2025, 21:06 UTC

Market Talk

Bank of Mexico Seen Likely to Slow Pace of Rate Cuts -- Market Talk

26 juin 2025, 21:05 UTC

Acquisitions, Fusions, Rachats

COUCHE-TARD RECEIVES FTC CLEARANCE TO COMPLETE ACQUISITION OF GETGO CAFÉ + MARKET >ATD.T

26 juin 2025, 21:05 UTC

Acquisitions, Fusions, Rachats

COUCHE-TARD RECEIVES FTC CLEARANCE TO COMPLETE ACQUISITION OF GETGO CAFÉ + MARKET >ATD.T

26 juin 2025, 20:52 UTC

Résultats

Nike 4Q Profit, Rev Slide as Turnaround Strategy Plays Out

26 juin 2025, 20:51 UTC

Résultats

Correct: Nike 4Q Net $211M, Not $200M >NKE

26 juin 2025, 20:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

26 juin 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

Comparaison

Variation de prix

GlycoMimetics Inc prévision

Objectif de Prix

By TipRanks

43.79% hausse

Prévisions sur 12 Mois

Moyen 22 USD  43.79%

Haut 22 USD

Bas 22 USD

Basé sur 2 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat

2 ratings

2

Achat

0

Maintien

0

Vente

Score Technique

By Trading Central

0.2416 / 0.261Support & Résistance

Court Terme

Bearish Evidence

Moyen Terme

Bullish Evidence

Long Terme

Weak Bearish Evidence

Éléments financiers

$

À Propos GlycoMimetics Inc

GlycoMimetics, Inc., a biotechnology company, focuses on the discovery and development of therapies for cancers and inflammatory diseases in the United States. It develops uproleselan, an E-selectin antagonist, which is used in combination with chemotherapy to treat acute myeloid leukemia (AML), as well as completed phase 3 trial to treat relapsed/refractory AML. The company also develops various other programs, including GMI-1687, an antagonist of E-selectin to treat vaso-occlusive crisis; and GMI-2093, a galectin-3 carbohydrate-binding protein. In addition, its portfolio comprises GMI-1359, which targets e-selectin and a chemokine receptor for the treatment of osteosarcoma. The company has a cooperative research and development agreement with the National Cancer Institute; and a collaboration and license agreement with Apollomics (Hong Kong) Limited for the development and commercialization of uproleselan and GMI-1687. GlycoMimetics, Inc. was incorporated in 2003 and is headquartered in Rockville, Maryland.